Azithromycin therapy during respiratory syncytial virus bronchiolitis: Upper airway microbiome alterations and subsequent recurrent wheeze

J Allergy Clin Immunol. 2016 Oct;138(4):1215-1219.e5. doi: 10.1016/j.jaci.2016.03.054. Epub 2016 May 18.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Azithromycin / therapeutic use*
  • Bronchiolitis, Viral / drug therapy*
  • Bronchiolitis, Viral / immunology
  • Bronchiolitis, Viral / microbiology*
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Microbiota / drug effects*
  • Microbiota / immunology
  • Moraxella / drug effects
  • Moraxella / immunology
  • Respiratory Sounds / drug effects*
  • Respiratory Sounds / immunology
  • Respiratory Syncytial Virus Infections / drug therapy*
  • Respiratory Syncytial Virus Infections / immunology
  • Respiratory Syncytial Virus Infections / microbiology*
  • Respiratory Syncytial Virus, Human
  • Respiratory System / drug effects
  • Respiratory System / immunology
  • Respiratory System / microbiology

Substances

  • Anti-Bacterial Agents
  • Azithromycin